Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Avalanche Biotechnologies Inc (NASDAQ: AAVL) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Avalanche Biotechnologies Inc (NASDAQ: AAVL) concerning whether a series of statements by Avalanche Biotechnologies Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 15, 2015, Avalanche reported that the Company's results from its Phase IIa trial of its gene therapy treatment for wet age-related macular degeneration met its primary endpoint. In a conference call, after the close of trading on June 15, 2015, however, the Company indicated that the study wasn't designed to show statistically significant differences between active and control groups.

Following the release of this news, shares of Avalanche declined $21.88 per share, or 56%, closing at $17.05 per share on June 16, 2015.

Based in Menlo Park, CA and founded in 2006, Avalanche Biotechnologies Inc is a clinical-stage biotechnology company that discovers and develops novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform.

If you purchased shares of Avalanche Biotechnologies Inc (NASDAQ: AAVL) on or before June 15, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185